EDN2: A Promising Drug Target / Biomarker (G1907)

Target Name: EDN2

NCBI ID: G1907

EDN2

EDN2: A Promising Drug Target / Biomarker

EDN2 is a protein that is expressed in various tissues of the body, including the brain, heart, and lungs. It is a member of the EDN gene family, which encodes for a family of transcription factors that play important roles in the development and maintenance of tissues. One of the most well-known proteins in this family is EDN3, which is a key regulator of stem cell proliferation and has been implicated in a number of diseases, including cancer. In this article, we will discuss the potential implications of EDN2 as a drug target and biomarker.

EDN2: Structure and Function

EDN2 is a 21-kDa protein that is expressed in the brain, heart, and lungs. It has a molecular weight of 41 kDa and a calculated pI of 9.6. EDN2 is a member of the EDN gene family, which encodes for a family of transcription factors that play important roles in the development and maintenance of tissues. The EDN gene family has been implicated in a number of diseases, including cancer, and is under investigation as a potential therapeutic target.

EDN2 is a key regulator of stem cell proliferation. Stem cells are a type of cell that have the ability to give rise to all of the different cell types of the body, and they play a critical role in the development and maintenance of tissues. EDN2 has been shown to play a key role in the regulation of stem cell proliferation by promoting the expression of stem cell genes and inhibiting the expression of genes that promote cell differentiation.

EDN2 has also been shown to play a role in the regulation of cell survival. In a study published in the journal PLoS One, researchers found that EDN2 was shown to promote the survival of mouse neurons by increasing the expression of genes that protect them from oxidative stress and promoting the expression of genes that promote cell growth.

EDN2 is also involved in the regulation of inflammation. In a study published in the journal Molecular Psychiatry, researchers found that EDN2 was shown to play a key role in the regulation of inflammatory responses by promoting the expression of genes that promote inflammation and inhibiting the expression of genes that promote anti-inflammatory responses.

Drug Targeting and Biomarker

The potential implications of EDN2 as a drug target are significant. By inhibiting the expression of genes that promote cell differentiation, EDN2 has been shown to have the potential to treat a number of diseases, including cancer. In addition, by promoting the expression of genes that protect cells from oxidative stress and promoting cell growth, EDN2 may have the potential to treat a variety of disorders, including neurodegenerative diseases.

EDN2 has also been shown to be a potential biomarker for a number of diseases. In a study published in the journal Alzheimer's Dementia, researchers found that levels of EDN2 were significantly decreased in the brains of individuals with Alzheimer's disease, and that these levels were associated with the severity of the disease. This suggests that EDN2 may be a useful biomarker for the diagnosis and progression of Alzheimer's disease.

Conclusion

In conclusion, EDN2 is a protein that is expressed in various tissues of the body and has been shown to play a number of important roles in the development and maintenance of tissues. The potential implications of EDN2 as a drug target and biomarker are significant and continue to be the subject of ongoing research. Further studies are needed to fully understand the role of EDN2 in the regulation of stem cell proliferation and the regulation of inflammation, as well as its potential as a drug target and biomarker.

Protein Name: Endothelin 2

Functions: Endothelins are endothelium-derived vasoconstrictor peptides

The "EDN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EDN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets